Equity Details
Price & Market Data
Price: $14.81
Daily Change: +$0.45 / 3.04%
Daily Range: $14.33 - $14.94
Market Cap: $1,065,204,544
Daily Volume: 1,099,875
Performance Metrics
1 Week: -0.07%
1 Month: 29.70%
3 Months: 32.14%
6 Months: 124.0%
1 Year: 288.9%
YTD: -14.06%
About Omeros Corporation (OMER)
Your daily market report for Omeros Corporation (OMER). Price: 14.81, daily change: +$0.45 / 3.04%. Market cap: 1,065,204,544. Full performance analysis from YTD to 52-week.
Company Details
Employees: 175
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.